Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115388) titled 'Lipoic acid as adjunctive therapy for sepsis-related moderate-to-severe ARDS: a single-center, randomized, double-blind, placebo-controlled phase II trial' on Dec. 25, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Weifang People's Hospital
Condition:
acute respiratory distress syndrome (ARDS)
Intervention:
ALA group:Intravenous infusion of lipoic acid at a dose of 600mg once a day for 7 consecutive days
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-01-01
Target Sample Size: ALA group:40;Control group:40;
Countries of Recruitment:
China...